The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 01, 2019

Filed:

Aug. 24, 2016
Applicant:

University of Florida Research Foundation, Inc., Gainesville, FL (US);

Inventors:

Mavis Agbandje-McKenna, Gainesville, FL (US);

William W. Hauswirth, Gainesville, FL (US);

Arun Srivastava, Gainesville, FL (US);

Li Zhong, Boxborough, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); A61K 45/06 (2006.01); C07K 14/72 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); C07K 14/70571 (2013.01); C07K 14/723 (2013.01); C12N 15/86 (2013.01); C12N 2710/10043 (2013.01); C12N 2799/025 (2013.01); C12N 2830/008 (2013.01);
Abstract

Disclosed are capsid-mutated rAAV vectors and methods for their use in gene therapy, and particularly for use in delivering therapeutic transgenes to treat a variety of mammalian diseases and disorders, including dysfunctions and abnormal conditions of the human eye. VP3 capsid proteins comprising a modification of one or more of the surface-exposed tyrosine residues are disclosed, and in particular, VP3 capsid protein comprising tyrosine-to-phenylalanine mutations at positions corresponding to Y444F, Y500F, and Y730F of the wild-type AAV2 sequence. Also provided are rAAV virions and viral particles that comprise such a mutated AAV capsid protein and a nucleic acid molecule that expresses one or more selected therapeutic or reporter transgenes in one or more mammalian cells of interest. Advantageously, the capsid-mutated rAAV vectors and virions disclosed herein afford improved transduction efficiency in a variety of cells, tissues and organs of interest, when compared to their unmodified (i.e., wild-type) rAAV vector counterparts.


Find Patent Forward Citations

Loading…